(±)-Voriconazole(CAS: 188416-29-7)

(±)-Voriconazole is subject to regulatory guidelines such as GHS classification, which categorizes it as a skin and eye irritant. It is also regulated under REACH in the EU, requiring registration for substances above 1 tonne per year. FDA and EPA guidelines also apply, particularly for its use in pharmaceuticals and environmental release criteria.

Alternatives to (±)-Voriconazole include other azole antifungals like posaconazole and itraconazole. In synthesis, isomers and analogs such as (S)- and (R)-Voriconazole can be used. Common alternative reagents include chloroacetyl chloride and acetic anhydride, depending on the specific synthesis pathway.

The market for (±)-Voriconazole is stable, driven by its use in treating severe fungal infections. Research trends include developing more targeted and less toxic antifungal agents. Market analysis shows a slight decline in usage, possibly due to the emergence of newer, more effective antifungals. However, there is ongoing interest due to its broad-spectrum activity against fungal pathogens.

Waste containing (±)-Voriconazole should be collected in appropriate lined containers, labeled accordingly. For disposal, it is recommended to use professional waste disposal services, ensuring compliance with local regulations. Incineration or chemical neutralization may be necessary, depending on local disposal methods. Environmental protection measures include proper containment to prevent spillage and contamination of soil and water sources.